1. Home
  2. ARVN vs CTKB Comparison

ARVN vs CTKB Comparison

Compare ARVN & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARVN
  • CTKB
  • Stock Information
  • Founded
  • ARVN 2015
  • CTKB 1990
  • Country
  • ARVN United States
  • CTKB United States
  • Employees
  • ARVN N/A
  • CTKB N/A
  • Industry
  • ARVN Biotechnology: Pharmaceutical Preparations
  • CTKB Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • ARVN Health Care
  • CTKB Health Care
  • Exchange
  • ARVN Nasdaq
  • CTKB Nasdaq
  • Market Cap
  • ARVN 456.2M
  • CTKB 526.7M
  • IPO Year
  • ARVN 2018
  • CTKB 2021
  • Fundamental
  • Price
  • ARVN $7.61
  • CTKB $3.92
  • Analyst Decision
  • ARVN Buy
  • CTKB Hold
  • Analyst Count
  • ARVN 22
  • CTKB 4
  • Target Price
  • ARVN $20.02
  • CTKB $6.00
  • AVG Volume (30 Days)
  • ARVN 1.3M
  • CTKB 932.3K
  • Earning Date
  • ARVN 10-29-2025
  • CTKB 11-04-2025
  • Dividend Yield
  • ARVN N/A
  • CTKB N/A
  • EPS Growth
  • ARVN N/A
  • CTKB N/A
  • EPS
  • ARVN N/A
  • CTKB N/A
  • Revenue
  • ARVN $372,800,000.00
  • CTKB $196,035,000.00
  • Revenue This Year
  • ARVN $1.61
  • CTKB $0.09
  • Revenue Next Year
  • ARVN N/A
  • CTKB $7.45
  • P/E Ratio
  • ARVN N/A
  • CTKB N/A
  • Revenue Growth
  • ARVN 299.57
  • CTKB N/A
  • 52 Week Low
  • ARVN $5.90
  • CTKB $2.37
  • 52 Week High
  • ARVN $29.61
  • CTKB $7.63
  • Technical
  • Relative Strength Index (RSI)
  • ARVN 49.90
  • CTKB 49.11
  • Support Level
  • ARVN $7.58
  • CTKB $3.80
  • Resistance Level
  • ARVN $7.89
  • CTKB $4.14
  • Average True Range (ATR)
  • ARVN 0.37
  • CTKB 0.21
  • MACD
  • ARVN -0.03
  • CTKB -0.03
  • Stochastic Oscillator
  • ARVN 18.42
  • CTKB 41.24

About ARVN Arvinas Inc.

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

About CTKB Cytek Biosciences Inc.

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Share on Social Networks: